Clear Harbor Asset Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Clear Harbor Asset Management acquired 7,610 Regeneron shares worth approximately $4.75 million in the second quarter. Institutional investors collectively own 83.31% of REGN.
• Regeneron reported strong quarterly results, with EPS of $14.29 surpassing estimates of $10.16 and revenue rising 16.7% year over year to $4.29 billion. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $801.70.
• The FDA approved Pasatru for a rare bone disorder, potentially expanding Regeneron’s rare-disease revenue, while its obesity-drug program offers additional growth potential. However, litigation tied to alleged disclosures about the Fianlimab-Libtayo melanoma trial presents legal and reputational risks.

Clear Harbor Asset Management LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,610 shares of the biopharmaceutical company's stock, valued at approximately $4,745,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. WPG Advisers LLC grew its stake in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 25 shares during the last quarter. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $26,000. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $29,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $834.04 on Friday. The stock has a fifty day moving average price of $697.09 and a 200 day moving average price of $716.73. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market cap of $85.87 billion, a PE ratio of 20.61, a P/E/G ratio of 1.42 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals's revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company posted $12.81 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is presently 9.29%.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wells Fargo & Company upped their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. Weiss Ratings reissued a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 15th. Truist Financial increased their target price on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Finally, Benchmark raised Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price target on the stock in a report on Tuesday, July 7th. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $801.70.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of the company's stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares of the company's stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the transaction, the director owned 603 shares of the company's stock, valued at $482,400. The trade was a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock valued at $1,090,030 in the last three months. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source